Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells

Biochemical Pharmacology

Volumn 82, Issue 11, 2011, Pages 1720-1730

  Okumura, Manabu ^a   Iwakiri, Tomomi ^a   Takagi, Akinori ^a   Hirabara, Yasutoshi ^a   Kawano, Yohei ^a   Arimori, Kazuhiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

CES; CPT 11; Hepatocyte growth factor; SN 38; UGT1A1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; A 6730; CARBOXYLESTERASE; CRYPTOTANSHINONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; JANUS KINASE 2 INHIBITOR; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN KINASE B INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; TYRPHOSTIN; UNCLASSIFIED DRUG; WP 1066;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL STRAIN HEPG2; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARBOXYLESTERASE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; GLUCURONOSYLTRANSFERASE; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 80255131069     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.095     Document Type: Article

References (37)

1. J.Y. Han, J.Y. Kim, S.H. Lee, N.J. Yoo, and B.G. Choi Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer Lung Cancer 2011
2. J.M. Siegfried, L.A. Weissfeld, J.D. Luketich, R.J. Weyant, C.T. Gubish, and R.J. Landreneau The clinical significance of hepatocyte growth factor for non-small cell lung cancer Ann Thorac Surg 66 1998 1915 1918 (Pubitemid 29087181)
3. T. Fukuura, C. Miki, T. Inoue, K. Matsumoto, and H. Suzuki Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma Br J Cancer 78 1998 454 459 (Pubitemid 28360631)
4. P. Vejchapipat, P. Tangkijvanich, A. Theamboonlers, V. Chongsrisawat, S. Chittmittrapap, and Y. Poovorawan Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma J Gastroenterol 39 2004 1182 1188 (Pubitemid 40074285)
5. M.T. Donato, M.J. Gomez-Lechon, R. Jover, T. Nakamura, and J.V. Castell Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture J Pharmacol Exp Ther 284 1998 760 767 (Pubitemid 28086669)
6. T. Iwakiri, M. Okumura, N. Matsunaga, E. Ichihara, S. Shiotsuki, and M. Nagata Hepatocyte growth factor increases uptake of estradiol 17β-d-glucuronide and Oatp1 protein level in rat hepatocytes Eur J Pharmacol 580 2008 19 26
7. G.G. Chabot Clinical pharmacokinetics of irinotecan Clin Pharmacokinet 33 1997 245 259 (Pubitemid 27429892)
8. K. Takasuna, T. Hagiwara, M. Hirohashi, M. Kato, M. Nomura, and E. Nagai Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats Cancer Res 56 1996 3752 3757 (Pubitemid 26272025)
9. R.H. Mathijssen, R.J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, and G. Stoter Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2001 2182 2194 (Pubitemid 32751614)
10. F. Innocenti, W. Liu, P. Chen, A.A. Desai, S. Das, and M.J. Ratain Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes Pharmacogenet Genomics 15 2005 295 301 (Pubitemid 40676550)
11. L. Iyer, C.D. King, P.F. Whitington, M.D. Green, S.K. Roy, and T.R. Tephly Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 1998 847 854 (Pubitemid 28096082)
12. F. Innocenti, S.D. Undevia, L. Iyer, P.X. Chen, S. Das, and M. Kocherginsky Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 2004 1382 1388 (Pubitemid 41103619)
13. A. Kojima, N.R. Hackett, and R.G. Crystal Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA Cancer Res 58 1998 4368 4374 (Pubitemid 28450039)
14. C. Raynal, J.M. Pascussi, G. Leguelinel, C. Breuker, J. Kantar, and B. Lallemant Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation Mol Cancer 9 2010 46
15. Y. Xu, and M.A. Villalona-Calero Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann Oncol 13 2002 1841 1851 (Pubitemid 36040772)
16. J.Y. Han, H.S. Lim, E.S. Shin, Y.K. Yoo, Y.H. Park, and J.E. Lee Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin J Clin Oncol 24 2006 2237 2244
17. F. Innocenti, D.L. Kroetz, E. Schuetz, M.E. Dolan, J. Ramirez, and M. Relling Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics J Clin Oncol 27 2009 2604 2614
18. R.P. Ramchandani, Y. Wang, B.P. Booth, A. Ibrahim, J.R. Johnson, and A. Rahman The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity J Clin Pharmacol 47 2007 78 86 (Pubitemid 44974001)
19. J.M. Hoskins, R.M. Goldberg, P. Qu, J.G. Ibrahim, and H.L. McLeod UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 2007 1290 1295 (Pubitemid 47394168)
20. T.W. Kim, and F. Innocenti Insights, challenges, and future directions in irinogenetics Ther Drug Monit 29 2007 265 270 (Pubitemid 47262254)
21. M.S. Braun, S.D. Richman, L. Thompson, C.L. Daly, A.M. Meade, and J.W. Adlard Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial J Clin Oncol 27 2009 5519 5528
22. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1951 265 275
23. J. Han, Y. Tsukada, E. Hara, N. Kitamura, and T. Tanaka Hepatocyte growth factor induces redistribution of p21(CIP1) and p27(KIP1) through ERK-dependent p16(INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells J Biol Chem 280 2005 31548 31556 (Pubitemid 41291898)
24. J. Sugatani, M. Osabe, M. Kurosawa, N. Kitamura, A. Ikari, and M. Miwa Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression Drug Metab Dispos 38 2010 177 186
25. K. Noda, Y. Nishiwaki, M. Kawahara, S. Negoro, T. Sugiura, and A. Yokoyama Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91 (Pubitemid 34438898)
26. J.Y. Douillard, D. Cunningham, A.D. Roth, M. Navarro, R.D. James, and P. Karasek Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
27. L.P. Rivory, J.F. Riou, M.C. Haaz, S. Sable, M. Vuilhorgne, and A. Commercon Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients Cancer Res 56 1996 3689 3694 (Pubitemid 26272014)
28. H.M. Dodds, M.C. Haaz, J.F. Riou, J. Robert, and L.P. Rivory Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38 J Pharmacol Exp Ther 286 1998 578 583 (Pubitemid 28318036)
29. T. Iwakiri, M. Okumura, Y. Kumagai, E. Ichihara, Y. Kawano, and K. Arimori Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes J Appl Toxicol 28 2008 329 336 (Pubitemid 351518120)
30. A. Sparreboom, R. Danesi, Y. Ando, J. Chan, and W.D. Figg Pharmacogenomics of ABC transporters and its role in cancer chemotherapy Drug Resist Updat 6 2003 71 84 (Pubitemid 36565766)
31. A. Guo, J. Villen, J. Kornhauser, K.A. Lee, M.P. Stokes, and K. Rikova Signaling networks assembled by oncogenic EGFR and c-Met Proc Natl Acad Sci U S A 105 2008 692 697 (Pubitemid 351171770)
32. K.L. Mueller, L.A. Hunter, S.P. Ethier, and J.L. Boerner Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells Cancer Res 68 2008 3314 3322
33. T. Yamauchi, N. Yamauchi, K. Ueki, T. Sugiyama, H. Waki, and H. Miki Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer J Biol Chem 275 2000 33937 33944
34. T.E. Reznik, Y. Sang, Y. Ma, R. Abounader, E.M. Rosen, and S. Xia Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor Mol Cancer Res 6 2008 139 150 (Pubitemid 351378174)
35. A.R. Bonine-Summers, M.E. Aakre, K.A. Brown, C.L. Arteaga, J.A. Pietenpol, and H.L. Moses Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells Cancer Biol Ther 6 2007 561 570 (Pubitemid 47328331)
36. K.P. Xu, and F.S. Yu Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing Invest Ophthalmol Vis Sci 48 2007 2242 2248
37. Z. Tang, R. Du, S. Jiang, C. Wu, D.S. Barkauskas, and J. Richey Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer Br J Cancer 99 2008 911 922